Alchemy Creative, Inc.

Alchemy Creative, Inc.

ALMY
Alchemy Creative, Inc.US flagOther OTC
0.00
USD
- -
- -
53.00Market Cap
No data availableFinancial data will appear here once available

Capital Structure

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Revenue

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Earnings Per Share

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Dividends Per Share

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Company Description

APIChat
CEO
D. Spencer Riley
Full Time Employees
37
Sector
Communication Services
Industry
Telecommunications Services
Address
130 Parkhouse Street Dallas TX United States of America 75207
IPO Date
Feb 14, 2001
Business
Alchemy Creative, Inc. (ALMY) operates as an early-stage venture holding company focused on biopharmaceutical, edutainment, nanotechnology, and developmental research enterprises; it develops, produces, and distributes DVDs, 3-D cartoons, and online games, alongside derivative products based on elemental adventures. The company maintains operations primarily in the United States, with headquarters located at 130 Parkhouse Street, Dallas, Texas 75207, and was founded in 1986, originally incorporated as Method Products Corp. before changing its name to Alchemy Creative, Inc. in November 2007. Through its subsidiaries, including NanoLand U.S.A., Inc., Alchemy Creative engages in advanced materials research, notably entering the carbon nanotube sector; NanoLand has advanced nanotechnology research initiatives, appointed Dr. Tsuruoka as Chief Technology Officer, and executed an international joint venture with Cargico Taiwan. Recent activities encompass these subsidiary developments in nanotechnology commercialization, alongside ongoing focus on edutainment content creation and biopharmaceutical ventures, reflecting strategic expansions in high-growth technology and research sectors within the past several years.